Conservative Management in Patients Diagnosed With Grade 2 or Grade 3 CIN

Sponsor
FundaciĆ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (Other)
Overall Status
Unknown status
CT.gov ID
NCT04115787
Collaborator
(none)
104
1
2.5
42.2

Study Details

Study Description

Brief Summary

Consecutive inclusion and collection of information for all women attending the Cervical Disease Unit with an histological diagnosis of grade 2 or grade 3 CIN during the last 5 years, from January 2012 to December 2016, which meet the inclusion criteria, have voluntarily manifested pregnancy intendedness and had a minimum follow-up time of 2 years and a maximum of 7.

The aim is to evaluate whether the HSIL resolution rates (CIN 2 or CIN 3) are sufficient to support conservative management.

Detailed Description

Follow-up is performed every 4 months with colposcopy, cytology and biopsies. Colposcopy and cytology are performed for all control subjects. The need for biopsy is established according to the colposcopy exam findings to confirm H-SIL or cervical cancer. Follow-up is spaced every 6 months if the cytology and biopsy results indicate L-SIL / ASCUS in agreement with the colposcopic image. HPV tests are performed every 8-12 months. This strategy is maintained until the resolution of the H-SIL.

The conservative management stops if the H-SIL lesion persists after 24 months of follow-up, if the inclusion criteria are no longer met or if the exclusion ones are met.

Inclusion and exclusion criteria are reviewed at each visit and the conservative management ceases in case the patient decides to undergo conization.

Study Design

Study Type:
Observational
Anticipated Enrollment :
104 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Conservative Management in Patients Diagnosed With Grade 2 or Grade 3 CIN
Anticipated Study Start Date :
Oct 14, 2019
Anticipated Primary Completion Date :
Nov 28, 2019
Anticipated Study Completion Date :
Dec 28, 2019

Outcome Measures

Primary Outcome Measures

  1. H-SIL Resolution [24 months]

    In cases where H-SIL (cytologic, histological and colposcopic) is no longer detected during follow-up. Include the strict resolution, indulgent resolution and regression

  2. H-SIL Regression [24 months]

    H-SIL is not detected, but with a low grade cytological, histologic or colposcopic lesion

Secondary Outcome Measures

  1. Factors probably related to the resolution [24 months]

    Demographics (age and origin), viral type, cytology, biopsy and colposcopy will be recorded at the beginning and end of the follow-up, as well as time until resolution, regression or progression and conization result.

  2. Strict resolution [24 months]

    Negative HPV determination or different from the initial

  3. Lenient resolution [24 months]

    Colposcopy lesion disappearance, negative results on cytology and biopsies with persistence of the same viral type of high initial grade.

  4. Conization surgery [24 months]

    Patients undergoing surgery

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Reproductive age and willing to get pregnant in the future

  • Acceptance of conservative management

  • Commitment to study visits.

  • Colposcopy with zone of transformation (ZT) type 1 or 2 (Unio esco-columnar totally visible) with image compatible with H-SIL and visible in its entirety.

Exclusion Criteria:
  • Pregnant women

  • Immunosuppression for human immunodeficiency virus (HIV) or iatrogenic type

  • suspicion or diagnosis of Glandular Cell Atipia (ACG), Adenocarcinoma in situ (AIS) or cervical cancer (CC)

  • Provided that inclusion criteria are not met

Contacts and Locations

Locations

Site City State Country Postal Code
1 Nerea Luqui Scarcelli Barcelona Spain 08041

Sponsors and Collaborators

  • FundaciĆ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
FundaciĆ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
ClinicalTrials.gov Identifier:
NCT04115787
Other Study ID Numbers:
  • IIBSP-CIN-2019-50
First Posted:
Oct 4, 2019
Last Update Posted:
Oct 4, 2019
Last Verified:
Oct 1, 2019
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 4, 2019